Non-invasive prescreening and drug efficacy evaluation, at scale.

Partner with Us

Remote eye tracking is an optimal integration for neuropharma R&D in which iteration speed is impaired by existing slow & clunky hardware-based methods

Neuropharma

Elevate your trial success rates and unlock breakthrough treatments

Partner with us

Leverage our novel biometric diagnostic tools to improve therapeutic strategies.

Contact

Enhance Efficacy Demonstration

Provides continuous, real-time monitoring of disease progression and treatment effects
Offers a comprehensive set of digital biometrics for nuanced disease assessment
Increases the sensitivity of outcome measurements in neuropharma trials

Provides continuous, real-time monitoring of disease progression and treatment effects
Offers a comprehensive set of digital biometrics for nuanced disease assessment
Increases the sensitivity of outcome measurements in neuropharma trials

Optimize Clinical Trial Screening

Accelerates participant recruitment process, potentially shortening trial timelines

Lowers costs associated with participant screening and recruitment
Improves the quality and suitability of selected trial participants

Accelerates participant recruitment process, potentially shortening trial timelines

Lowers costs associated with participant screening and recruitment
Improves the quality and suitability of selected trial participants

"To date, we’ve used the MMSE and MoCA as a proxy for cognitive health in our liquid Donepezil drug trials. We found that the quantitative results they provide lack a degree of specificity crucial for the statistical rigor we uphold at Brio - which Vytal is able to deliver."

— COO, Brio Pharmaceuticals

Current State of Neuropharma

New drug development costs exceed

Alzheimer's disease trials often have screen failure rates ranging from

Alzheimer's disease trials often have screen failure rates exceeding

Alzheimer's disease trials often have screen failure rates ranging from

Current drug candidate failure rate in clinical trials due to insufficient clinical efficacy data is

Current drug candidate failure rate in clinical trials due to insufficient clinical efficacy data exceeds

Current drug candidate failure rate in clinical trials due to insufficient clinical efficacy data is

Neurology Phase 1 approval likelihood is

Eye movement biometrics can be used to evaluate: